Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.

Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL.

J Clin Oncol. 2005 Nov 1;23(31):7897-903.

2.

Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.

Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J.

J Urol. 2006 Jan;175(1):136-9; discussion 139.

PMID:
16406890
3.

Fracture risk in Danish men with prostate cancer: a nationwide register study.

Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K.

BJU Int. 2007 Oct;100(4):749-54.

4.

Incidence of fractures causing hospitalisation in prostate cancer patients: results from the population-based PCBaSe Sweden.

Thorstenson A, Bratt O, Akre O, Hellborg H, Holmberg L, Lambe M, Bill-Axelson A, Stattin P, Adolfsson J.

Eur J Cancer. 2012 Jul;48(11):1672-81. doi: 10.1016/j.ejca.2012.01.035. Epub 2012 Mar 3.

PMID:
22386317
5.

Fracture risk in patients with prostate cancer on androgen deprivation therapy.

López AM, Pena MA, Hernández R, Val F, Martín B, Riancho JA.

Osteoporos Int. 2005 Jun;16(6):707-11. Epub 2005 Feb 16.

PMID:
15714259
6.

Incidence and risk factors for low trauma fractures in men with prostate cancer.

Ahlborg HG, Nguyen ND, Center JR, Eisman JA, Nguyen TV.

Bone. 2008 Sep;43(3):556-60. doi: 10.1016/j.bone.2008.05.003. Epub 2008 May 11.

PMID:
18585119
7.

Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma.

Townsend MF, Sanders WH, Northway RO, Graham SD Jr.

Cancer. 1997 Feb 1;79(3):545-50.

PMID:
9028366
8.

Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.

Krupski TL, Foley KA, Baser O, Long S, Macarios D, Litwin MS.

J Urol. 2007 Oct;178(4 Pt 1):1423-8. Epub 2007 Aug 16.

PMID:
17706711
9.

Therapy Insight: osteoporosis during hormone therapy for prostate cancer.

Smith MR.

Nat Clin Pract Urol. 2005 Dec;2(12):608-15; quiz 628. Review.

PMID:
16474548
10.

Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapy.

Krupski TL, Smith MR, Lee WC, Pashos CL, Brandman J, Wang Q, Botteman M, Litwin MS.

Cancer. 2004 Aug 1;101(3):541-9. Erratum in: Cancer. 2004 Nov 15;101(10):2370.

11.
13.

Skeletal fracture associated with androgen suppression induced osteoporosis: the clinical incidence and risk factors for patients with prostate cancer.

Oefelein MG, Ricchuiti V, Conrad W, Seftel A, Bodner D, Goldman H, Resnick M.

J Urol. 2001 Nov;166(5):1724-8.

PMID:
11586210
14.

Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer.

Hatano T, Oishi Y, Furuta A, Iwamuro S, Tashiro K.

BJU Int. 2000 Sep;86(4):449-52.

15.

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Smith MR, McGovern FJ, Zietman AL, Fallon MA, Hayden DL, Schoenfeld DA, Kantoff PW, Finkelstein JS.

N Engl J Med. 2001 Sep 27;345(13):948-55.

16.

Cross-sectional study of bone turnover during bicalutamide monotherapy for prostate cancer.

Smith MR, Fallon MA, Goode MJ.

Urology. 2003 Jan;61(1):127-31.

PMID:
12559282
17.

Bone health management in prostate cancer patients receiving androgen deprivation therapy.

Dhanapal V, Reeves DJ.

J Oncol Pharm Pract. 2012 Mar;18(1):84-90. doi: 10.1177/1078155211402105. Epub 2011 Aug 1.

PMID:
21807761
18.

Osteoporosis and obesity in men receiving hormone therapy for prostate cancer.

Smith MR.

J Urol. 2004 Nov;172(5 Pt 2):S52-6; discussion S56-7. Review.

PMID:
15535444
19.

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Michaelson MD, Kaufman DS, Lee H, McGovern FJ, Kantoff PW, Fallon MA, Finkelstein JS, Smith MR.

J Clin Oncol. 2007 Mar 20;25(9):1038-42.

20.

Timing of androgen deprivation therapy use and fracture risk among elderly men with prostate cancer in the United States.

Beebe-Dimmer JL, Cetin K, Shahinian V, Morgenstern H, Yee C, Schwartz KL, Acquavella J.

Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):70-8. doi: 10.1002/pds.2258. Epub 2011 Nov 24.

Items per page

Supplemental Content

Write to the Help Desk